Autism Spectrum Disorder Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global Autism Spectrum Disorders Treatment Market is Segmented by Drug Class (Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, and Other Drug Classes), By Type (Autistic Disorder, Asperger's Syndrome, and Other Types), By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Autism Spectrum Disorder Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Autism Spectrum Disorders Treatment Market Size

autism spectrum disorders treatment market
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 7.00 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Global Autism Spectrum Disorders Treatment Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Autism Spectrum Disorders Treatment Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Autism Spectrum Disorders Treatment Market Analysis

The Global Autism Spectrum Disorders Treatment Market is expected to register a CAGR of greater than 7% during the forecast period.

The COVID-19 pandemic has significantly impacted the autism disorders treatment market. This can be attributed to the fact that the pandemic caused supply chain disruptions in the pharmaceutical industry which led to problems in seeking treatment for autism spectrum disorders. Thus, the pandemic had a short-term negative impact on the market. In addition, as per a June 2021 published article titled, "Leveraging Technology for the Wellbeing of Individuals With Autism Spectrum Disorder and Their Families During Covid-19", one-way technology can be used during the pandemic for families with autism spectrum disorder (ASD) is through telehealth, which refers to providing various remote services electronically, such as patient care, education, and monitoring. Thus, telehealth has aided in meeting the rising demand for autism spectrum disorder treatment, thereby contributing to the market growth. Also, as per a December 2021 published study titled, "Coping with autism during lockdown period of the COVID-19 pandemic", the COVID-19 pandemic disrupted routines, triggered behavioral issues in individuals with ASD, and impacted the coping skills of both individuals and families, along with the mental health and well-being of the family. Such studies indicate the significantly high demand for autism spectrum disorders treatment amid the pandemic, thereby depicting an overall positive impact on the market.

The growth of the market can be attributed to the factors such as the increasing burden of autism spectrum disorder worldwide, rising awareness about the condition and available treatment options for autism spectrum disorder, as well as the growing number of investments in autism spectrum disorder.

For instance, as per a March 2022 update by the World Health Organization (WHO), about one in 100 children has autism. In addition, as per an October 2021 published study titled "Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review," thirteen studies on the prevalence of autism spectrum disorder and 33 on the prevalence of co-morbidities were included. Prevalence of ASD was 1.70 and 1.85% in the United States in children aged 4 and 8 years, respectively, while the prevalence in Europe ranged between 0.38 and 1.55%. Additionally, current evidence is supportive of a global increase in autism spectrum disorder prevalence over the past years. However, the growing number of investments is also a major factor driving the market growth. For instance, in November 2021, Yamo Pharmaceuticals, LLC, reported that The Autism Impact Fund had made a capital investment in Yamo to support a Phase II study of L1-79 in adolescents and adults with an autism spectrum disorder. L1-79, the company's lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in autism spectrum disorder (ASD) and thus impact the socialization and communication symptoms in individuals with ASD.

However, the high cost of autism spectrum disorder treatment and diagnosis, as well as stringent regulations about product approval, are the major factors hindering the market growth.

Autism Spectrum Disorders Treatment Industry Overview

The autism spectrum disorders treatment market is competitive and nearly consolidated with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are PaxMedica, Yamo Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd, and Q BioMed Inc., among other players.

Autism Spectrum Disorders Treatment Market Leaders

  1. PaxMedica

  2. Yamo Pharmaceuticals

  3. Otsuka Pharmaceutical Co., Ltd.

  4. F. Hoffmann-La Roche Ltd

  5. Q BioMed Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Q BioMed Inc., PaxMedica, Yamo Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd,  Curemark, LLC, Zynerba Pharmaceuticals, Inc
Need More Details on Market Players and Competiters?
Download PDF

Autism Spectrum Disorders Treatment Market News

  • In August 2022, Bened Life released the first gut-brain medical probiotic, Neuralli. Made in the United States and utilizing the patented probiotic strain L. plantarum PS128, Neuralli is designed to promote mental health and support neurological conditions including but not limited to Parkinson's disease (PD) and autism spectrum disorder (ASD).
  • In March 2022, STALICLA, a Swiss clinical-stage biotech company leading omics-based drug development for patients with neurodevelopmental disorders (NDDs), reported the highly successful completion of the phase 1b trials for its lead drug candidate STP1. These clinical data clear the way for the first application of STALICLA's precision medicine discovery platform in autism spectrum disorders.

Autism Spectrum Disorders Treatment Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Autism Spectrum Disorder (ASD) Worldwide
    • 4.2.2 Rising Awareness Pertaining ASD and Growing Number of Investments
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Autism Spectrum Disorder Treatment and Diagnosis
    • 4.3.2 Stringent Regulations Pertaining to Product Approval
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Drug Class
    • 5.1.1 Antipsychotic Drugs
    • 5.1.2 SSRIs/Antidepressants
    • 5.1.3 Stimulants
    • 5.1.4 Other Drug Classes
  • 5.2 By Type
    • 5.2.1 Autistic Disorder
    • 5.2.2 Asperger's Sydrome
    • 5.2.3 Other Types
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Drug Stores and Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle- East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Q BioMed Inc.
    • 6.1.2 PaxMedica
    • 6.1.3 Yamo Pharmaceuticals
    • 6.1.4 Otsuka Pharmaceutical Co., Ltd.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Curemark, LLC
    • 6.1.7 Zynerba Pharmaceuticals, Inc
    • 6.1.8 Axial Therapeutics
    • 6.1.9 Novartis AG
    • 6.1.10 STALICLA
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Autism Spectrum Disorders Treatment Industry Segmentation

As per the scope of the report, autism spectrum disorders constitute a diverse group of conditions related to the development of the brain and are characterized by some degree of difficulty with social interaction and communication. The market is segmented by drug class (antipsychotic drugs, selective serotonin reuptake inhibitors (SSRIs)/antidepressants, stimulants, and other drug classes), by type (autistic disorder, Asperger's Syndrome, and other types), by distribution channel (hospital pharmacies, drug stores and retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Drug Class Antipsychotic Drugs
SSRIs/Antidepressants
Stimulants
Other Drug Classes
By Type Autistic Disorder
Asperger's Sydrome
Other Types
By Distribution Channel Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Pharmacies
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle- East and Africa GCC
South Africa
Rest of Middle-East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Autism Spectrum Disorders Treatment Market Research FAQs

What is the current Global Autism Spectrum Disorders Treatment Market size?

The Global Autism Spectrum Disorders Treatment Market is projected to register a CAGR of greater than 7% during the forecast period (2025-2030)

Who are the key players in Global Autism Spectrum Disorders Treatment Market?

PaxMedica, Yamo Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd and Q BioMed Inc. are the major companies operating in the Global Autism Spectrum Disorders Treatment Market.

Which is the fastest growing region in Global Autism Spectrum Disorders Treatment Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Autism Spectrum Disorders Treatment Market?

In 2025, the North America accounts for the largest market share in Global Autism Spectrum Disorders Treatment Market.

What years does this Global Autism Spectrum Disorders Treatment Market cover?

The report covers the Global Autism Spectrum Disorders Treatment Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Autism Spectrum Disorders Treatment Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Autism Spectrum Disorders Treatment Industry Report

Statistics for the 2025 Global Autism Spectrum Disorders Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Autism Spectrum Disorders Treatment analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.